The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention

American Journal of Perinatology

Volumn 27, Issue 4, 2010, Pages 343-348

  Joy, Saju ^a   Rhea, Debbie J ^b   Istwan, Niki B ^b   Desch, Cheryl N ^b   Stanziano, Gary ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Women's and Children's Health   (United States)

Author keywords

17 hydroxyprogesterone caproate (17P); Maternal risk factors; Preterm birth prevention; Preterm labor; Recurrent preterm delivery

Indexed keywords

HYDROXYPROGESTERONE;

ADOLESCENT; ADULT; ARTICLE; CERCLAGE; CONFIDENCE INTERVAL; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MARRIAGE; MATERNAL AGE; MEDICAID; PATIENT EDUCATION; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SMOKING; TOBACCO;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL MONITORING; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; PROBABILITY; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 77949661883     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0029-1243306     Document Type: Article

References (14)

1. Martin J A., Hamilton B E., Sutton P D. et al. Births: final data for 2006. National Vital Statistics Reports; Vol. 57, No. 7 Hyattsville, MD National Center for Health Statistics 2009
2. Goldenberg R L., Culhane J F., Iams J D., Romero R. Epidemiology and causes of preterm birth. Lancet 2008 371 75-84
3. Holbrook R H. Jr, Laros R K. Jr, Creasy R K. Evaluation of a risk-scoring system for prediction of preterm labor. Am J Perinatol 1989 6 62-68
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 31. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol 2001 98 709-716
5. Meis P J., Klebanoff M, Thom E et al, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003 348 2379-2385
6. Rouse D J., Caritis S N., Peaceman A M. et al, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007 357 454-461
7. Caritis S N., Rouse D J., Peaceman A M. et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU). Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009 113 (2 Pt 1) 285-292
8. González-Quintero V H., Istwan N B., Rhea D J., Smarkusky L, Hoffman M C., Stanziano G J. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007 20 249-252
9. How H Y., Barton J R., Istwan N B., Rhea D J., Stanziano G J. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol 2007 197 260, e1-e4
10. Ventolini G, Duke J, Po W et al. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. J Reprod Med 2008 53 667-671
11. Rebarber A, Cleary-Goldman J, Istwan N B. et al. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Am J Perinatol 2008 25 271-275
12. Rittenberg C, Newman R B., Istwan N B., Rhea D J., Stanziano G J. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med 2009 54 47-52
13. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Women receiving 17 - hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance. Am J Obstet Gynecol 2008 199 389, e1-e4
14. Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008 112 963-965